Alzheimer’s disease is a prospect as frightening to many of us as cancer, and with poor treatment options. Most of the costly medications used in treating this type of dementia do little more than delay its progression by a few weeks or months. The idea that anything might be done to turn back the ravages of this memory robber has seemed an impossible dream.
Now, however, research shows that a novel, multi-faceted approach may be able to reverse cognitive decline. Nine of the first ten patients on this comprehensive, personalized therapeutic program have shown improvement not only on the markers of inflammation underlying Alzheimer’s disease, but also have had lasting improvement in measures of memory and ability to function and reason. What are the elements and lessons of this therapeutic system?
This Week’s Guest:
Dale Bredesen, MD, is the Augustus Rose Professor of Neurology and Director of the Easton Center for AlzheimerÕs Disease Research at UCLA. He is also Director of Neurodegenerative Disease Research at the David Geffen School of Medicine at UCLA and Founding President and CEO of the Buck Institute for Research on Aging.